# Biotech Daily Digest ‚Äî 2025-12-04

**46 items from 4 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 10 items
- Fierce Biotech: 7 items
- arXiv q-bio: 28 items


## Eli Lilly Press Releases

- **[U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor](https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-expanded-indication-lillys-jaypirca)**  
  _Wed, 03 Dec 2025 12:59:00 -0500_  
  Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded indication represents a substantial increase in the number of CLL/SLL patients who may benefit from


## Endpoints News

- **[Crescent forms PD-1xVEGF, ADC pact with Kelun, raises $185M](https://endpoints.news/crescent-forms-pd-1xvegf-adc-pact-with-kelun-raises-185m/)**  
  _Thu, 04 Dec 2025 14:04:35 +0000_  
  Crescent Biopharma made a set of sweeping moves Thursday morning, notably with its strategy of bringing its PD-1xVEGF to China.

 Boston-based Crescent signed a two-way deal with Kelun-Biotech, in which both companies will have access ...

- **[Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer‚Äôs Seagen](https://endpoints.news/daiichi-sankyo-avoids-payout-in-long-running-patent-dispute-with-pfizers-seagen/)**  
  _Thu, 04 Dec 2025 11:59:37 +0000_  
  Daiichi Sankyo said a US federal court has ruled in its favor in two patent disputes with Pfizer‚Äôs Seagen over a linker technology critical for antibody-drug conjugates. The latest turn of events lets Daiichi off ...

- **[Clinical trials tech startup Paradigm raises $78M, acquires part of Roche‚Äôs Flatiron](https://endpoints.news/clinical-trials-tech-startup-paradigm-raises-78m-acquires-part-of-roches-flatiron/)**  
  _Thu, 04 Dec 2025 11:00:00 +0000_  
  When Ken Frazier led Merck, one of the challenges of developing Keytruda was getting the blockbuster-to-be immunotherapy to a broad set of patients. Many patients who could have benefited from the drug couldn't access it ...

- **[Home care startup Inbound Health shuts down](https://endpoints.news/home-care-startup-inbound-health-shuts-down/)**  
  _Thu, 04 Dec 2025 02:28:00 +0000_  
  Home care startup Inbound Health shut down Monday after a deal to raise more money fell apart, Endpoints News has learned.

 It's the latest in a string of health tech closures, as investors who once ...

- **[FDA seeks to raise user fees for companies running Phase 1 trials outside the US](https://endpoints.news/fda-seeks-to-raise-user-fees-for-companies-running-phase-1-trials-outside-the-us/)**  
  _Wed, 03 Dec 2025 20:00:14 +0000_  
  The FDA wants to incentivize US-based drug development by adding new fees for companies that run their Phase 1 trials outside the country, according to meeting minutes shared by the agency ...

- **[With Phase 3 Duchenne success, Capricor plots path forward after FDA rejection](https://endpoints.news/with-phase-3-duchenne-success-capricor-plots-path-forward-after-fda-rejection/)**  
  _Wed, 03 Dec 2025 16:36:07 +0000_  
  Capricor Therapeutics said that its cell therapy for Duchenne muscular dystrophy met both a primary and key secondary endpoint in a Phase 3 trial, boosting the company‚Äôs odds for approval as it returns to the ...

- **[Black Diamond reports mid-stage lung cancer data, continues its hunt for a partner](https://endpoints.news/black-diamond-reports-mid-stage-lung-cancer-data-continues-its-hunt-for-a-partner/)**  
  _Wed, 03 Dec 2025 16:35:49 +0000_  
  Black Diamond Therapeutics reported preliminary Phase 2 data for its EGFR inhibitor in lung cancer, but said it will need to find a partner to be able to move into a registrational program.

 Instead, the ...

- **[Orion's ‚Ç¨180M milestone payment; Iolyx partners dry eye candidate](https://endpoints.news/orions-e180m-milestone-payment-iolyx-partners-dry-eye-candidate/)**  
  _Wed, 03 Dec 2025 15:28:34 +0000_  
  Plus, news about QurAlis, Clene, ADC Therapeutics and Junevity:

 üí∂ Orion to receive ‚Ç¨180M milestone payment: The cash will come from Bayer, on the back of sales of prostate cancer therapy Nubeqa. Subsequently, Orion also ...

- **[Pfizer-allied molecular glue startup Triana collects $120M Series B](https://endpoints.news/pfizer-allied-molecular-glue-startup-triana-collects-120m-series-b/)**  
  _Wed, 03 Dec 2025 15:28:30 +0000_  
  Triana Biomedicines has reeled in a $120 million Series B ‚Äî $10 million higher than its 2022 Series A ‚Äî to collect proof-of-concept data for its lead experimental medicine and ...

- **[Updated: Pharvaris‚Äô hereditary angioedema drug gets Phase 3 win](https://endpoints.news/pharvaris-hereditary-angioedema-drug-gets-phase-3-win/)**  
  _Wed, 03 Dec 2025 12:20:48 +0000_  
  Pharvaris‚Äô on-demand oral treatment for hereditary angioedema (HAE) attacks alleviated symptoms significantly faster than placebo, according to topline data from a Phase 3 trial released Wednesday.

 The drug, called deucrictibant, is ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/astrazenecas-latest-amyloidosis-pact-neurimmune-could-reach-780m" hreflang="en">AstraZeneca's latest amyloidosis pact with Neurimmune could reach $780M</a>](https://www.fiercebiotech.com/biotech/astrazenecas-latest-amyloidosis-pact-neurimmune-could-reach-780m)**  
  _Dec 4, 2025 7:34am_  
  Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to pick up a second asset.

- **[<a href="https://www.fiercebiotech.com/medtech/medtronics-hugo-surgical-robot-secures-us-clearance" hreflang="en">Medtronic's Hugo surgical robot secures US clearance</a>](https://www.fiercebiotech.com/medtech/medtronics-hugo-surgical-robot-secures-us-clearance)**  
  _Dec 3, 2025 2:30pm_  
  The FDA‚Äôs initial clearance includes procedures to remove the prostate, kidneys and bladder, which covers about 230,000 surgeries annually in the U.S.

- **[<a href="https://www.fiercebiotech.com/cro/next-gen-cro-avetra-unveils-access-350-us-sites" hreflang="en">Next-gen CRO Avetra unveils with access to 350-plus US sites </a>](https://www.fiercebiotech.com/cro/next-gen-cro-avetra-unveils-access-350-us-sites)**  
  _Dec 3, 2025 3:30pm_  
  A new CRO called Avetra has emerged with a mission of modernizing clinical research operations by prioritizing transparency and faster study starts.

- **[<a href="https://www.fiercebiotech.com/biotech/capricor-sets-2nd-approval-attempt-duchenne-cell-therapy-phase-3-win" hreflang="en">Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy</a>](https://www.fiercebiotech.com/biotech/capricor-sets-2nd-approval-attempt-duchenne-cell-therapy-phase-3-win)**  
  _Dec 3, 2025 10:48am_  
  Capricor Therapeutics has notched a key win in its efforts to bring Duchenne muscular dystrophy cell therapy deramiocel to market, hitting the primary endpoint in a phase 3 trial.

- **[<a href="https://www.fiercebiotech.com/biotech/pfizer-backed-triana-scores-120m-series-b-take-molecular-glue-degrader-clinic" hreflang="en">Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic</a>](https://www.fiercebiotech.com/biotech/pfizer-backed-triana-scores-120m-series-b-take-molecular-glue-degrader-clinic)**  
  _Dec 3, 2025 9:42am_  
  Triana Biomedicines has tapped Pfizer Ventures and a number of other existing and new investors to secure a $120 million series B the biotech will use to take its lead molecular glue degrader into the clinic.

- **[<a href="https://www.fiercebiotech.com/pharma/site-irregularities-bristol-myers-delays-key-cobenfy-readout-alzheimers-psychosis" hreflang="en">With site 'irregularities,' Bristol Myers delays key Cobenfy readout in Alzheimer's psychosis</a>](https://www.fiercebiotech.com/pharma/site-irregularities-bristol-myers-delays-key-cobenfy-readout-alzheimers-psychosis)**  
  _Dec 3, 2025 9:45am_  
  The highly anticipated Adept-2 study data will not read out by year-end as previously planned after BMS identified ‚Äúirregularities due to clinical trial execution at a small number of study sites,‚Äù the company said Wednesday.

- **[<a href="https://www.fiercebiotech.com/biotech/top-drug-regulator-richard-pazdur-set-retire-fda-stat" hreflang="en">UPDATE: BIO CEO warns industry at 'tipping point' as FDA's Pazdur plans departure</a>](https://www.fiercebiotech.com/biotech/top-drug-regulator-richard-pazdur-set-retire-fda-stat)**  
  _Dec 2, 2025 12:30pm_  
  Weeks after being named the nation‚Äôs top drug regulator, Richard Pazdur, M.D., has taken steps to retire as head of the FDA‚Äôs Center for Drug Evaluation and Research at the end of this month.


## arXiv q-bio

- **[An AI Implementation Science Study to Improve Trustworthy Data in a Large Healthcare System](https://arxiv.org/abs/2512.03098)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03098v1 Announce Type: new 
Abstract: The rapid growth of Artificial Intelligence (AI) in healthcare has sparked interest in Trustworthy AI and AI Implementation Science, both of which are essential for accelerating clinical adoption. However, strict regulations, gaps between research and clinical settings,‚Ä¶

- **[The BEAT-CF Causal Model: A model for guiding the design of trials and observational analyses of cystic fibrosis exacerbations](https://arxiv.org/abs/2512.03110)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03110v1 Announce Type: new 
Abstract: Loss of lung function in cystic fibrosis (CF) occurs progressively, punctuated by acute pulmonary exacerbations (PEx) in which abrupt declines in lung function are not fully recovered. A key component of CF management over the past half century has been the treatment of‚Ä¶

- **[PanFoMa: A Lightweight Foundation Model and Benchmark for Pan-Cancer](https://arxiv.org/abs/2512.03111)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03111v1 Announce Type: new 
Abstract: Single-cell RNA sequencing (scRNA-seq) is essential for decoding tumor heterogeneity. However, pan-cancer research still faces two key challenges: learning discriminative and efficient single-cell representations, and establishing a comprehensive evaluation benchmark. I‚Ä¶

- **[Beyond Bayesian Inference: The Correlation Integral Likelihood Framework and Gradient Flow Methods for Deterministic Sampling](https://arxiv.org/abs/2512.03122)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03122v1 Announce Type: new 
Abstract: Calibrating mathematical models of biological processes is essential for achieving predictive accuracy and gaining mechanistic insight. However, this task remains challenging due to limited and noisy data, significant biological variability, and the computational comple‚Ä¶

- **[A Comprehensive Review of Casein Kinase 2 in Drosophila Circadian Timing and Its Biomedical Relevance](https://arxiv.org/abs/2512.03191)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03191v1 Announce Type: new 
Abstract: Circadian rhythms are endogenous 24-hour oscillations that regulate physiology, metabolism, sleep-wake cycles, and cellular homeostasis. Drosophila melanogaster, a genetically tractable model organism, has played a foundational role in uncovering the molecular mechanism‚Ä¶

- **[Optimal Griffiths Phase in Heterogeneous Human Brain Networks: Brain Criticality Embracing Stability and Flexibility across Individuals](https://arxiv.org/abs/2512.03409)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03409v1 Announce Type: new 
Abstract: A prominent hypothesis in neuroscience proposes that brains achieve optimal performance by operating near a critical point. However, this framework, which often assumes a universal critical point, fails to account for the extensive individual variability observed in neu‚Ä¶

- **[Learning From Limited Data and Feedback for Cell Culture Process Monitoring: A Comparative Study](https://arxiv.org/abs/2512.03460)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03460v1 Announce Type: new 
Abstract: In cell culture bioprocessing, real-time batch process monitoring (BPM) refers to the continuous tracking and analysis of key process variables such as viable cell density, nutrient levels, metabolite concentrations, and product titer throughout the duration of a batch‚Ä¶

- **[Cell-cell communication inference and analysis: biological mechanisms, computational approaches, and future opportunities](https://arxiv.org/abs/2512.03497)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03497v1 Announce Type: new 
Abstract: In multicellular organisms, cells coordinate their activities through cell-cell communication (CCC), which are crucial for development, tissue homeostasis, and disease progression. Recent advances in single-cell and spatial omics technologies provide unprecedented oppor‚Ä¶

- **[Toward AI-Ready Medical Imaging Data](https://arxiv.org/abs/2512.03541)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03541v1 Announce Type: new 
Abstract: Medical imaging data plays a vital role in disease diagnosis, monitoring, and clinical research discovery. Biomedical data managers and clinical researchers must navigate a complex landscape of medical imaging infrastructure, input/output tools and data reliability work‚Ä¶

- **[Microclimatic variation in tropical canopies: A glimpse into the processes of community assembly in epiphytic bryophyte communities](https://arxiv.org/abs/2512.03585)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03585v1 Announce Type: new 
Abstract: Epiphytic communities offer an original framework to disentangle the contributions of environmental filters, biotic interactions and dispersal limitations to community structure at fine spatial scales. We determine here whether variations in light, microclimatic conditi‚Ä¶

- **[Generating a Contact Matrix for Aged Care Settings in Australia: an agent-based model study](https://arxiv.org/abs/2512.03866)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03866v1 Announce Type: new 
Abstract: This study presents an agent-based model (ABM) developed to simulate staff and resident interactions within a synthetic aged care facility, capturing movement, task execution, and proximity-based contact events across three staff shifts and varying levels of resident ca‚Ä¶

- **[Leveraging topological data analysis to estimate bone strength from micro-CT as a surrogate for advanced imaging](https://arxiv.org/abs/2512.03880)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03880v1 Announce Type: new 
Abstract: Accurate bone strength prediction is essential for assessing fracture risk, particularly in aging populations and individuals with osteoporosis. Bone imaging has evolved from X-rays and DXA to clinical computed tomography (CT), and now to advanced modalities such as hig‚Ä¶

- **[Emergent Spatiotemporal Dynamics in Large-Scale Brain Networks with Next Generation Neural Mass Models](https://arxiv.org/abs/2512.03907)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03907v1 Announce Type: new 
Abstract: Understanding the dynamics of large-scale brain models remains a central challenge due to the inherent complexity of these systems. In this work, we explore the emergence of complex spatiotemporal patterns in a large scale-brain model composed of 90 interconnected brain‚Ä¶

- **[Approximate Bayesian Inference on Mechanisms of Network Growth and Evolution](https://arxiv.org/abs/2512.03092)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03092v1 Announce Type: cross 
Abstract: Mechanistic models can provide an intuitive and interpretable explanation of network growth by specifying a set of generative rules. These rules can be defined by domain knowledge about real-world mechanisms governing network growth or may be designed to facilitate th‚Ä¶

- **[Contrastive Deep Learning for Variant Detection in Wastewater Genomic Sequencing](https://arxiv.org/abs/2512.03158)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03158v1 Announce Type: cross 
Abstract: Wastewater-based genomic surveillance has emerged as a powerful tool for population-level viral monitoring, offering comprehensive insights into circulating viral variants across entire communities. However, this approach faces significant computational challenges ste‚Ä¶

- **[Prior preferences in active inference agents: soft, hard, and goal shaping](https://arxiv.org/abs/2512.03293)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03293v1 Announce Type: cross 
Abstract: Active inference proposes expected free energy as an objective for planning and decision-making to adequately balance exploitative and explorative drives in learning agents. The exploitative drive, or what an agent wants to achieve, is formalised as the Kullback-Leibl‚Ä¶

- **[Sleep Modulation: The Challenge of Transitioning from Open Loop to Closed Loop](https://arxiv.org/abs/2512.03784)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2512.03784v1 Announce Type: cross 
Abstract: Sleep disorders have emerged as a critical global health issue, highlighting the urgent need for effective and widely accessible intervention technologies. Non-invasive brain stimulation has garnered attention as it enables direct or indirect modulation of neural acti‚Ä¶

- **[DeepBioisostere: Discovering Bioisosteres with Deep Learning for a Fine Control of Multiple Molecular Properties](https://arxiv.org/abs/2403.02706)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2403.02706v2 Announce Type: replace 
Abstract: Optimizing molecular properties while preserving biological activity is a central challenge in drug design. Bioisosteric replacement, which substitutes a molecular fragment with a chemically or biologically analogous moiety, offers a powerful strategy for fine-tunin‚Ä¶

- **[Kubo-Martin-Schwinger states of Path-structured Flow in Directed Brain Synaptic Networks](https://arxiv.org/abs/2410.18222)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2410.18222v2 Announce Type: replace 
Abstract: The brain's synaptic network, characterized by parallel connections and feedback loops, drives interaction pathways between neurons through a large system with infinitely many degrees of freedom. This system is best modeled by the graph C*-algebra of the underlying‚Ä¶

- **[In Silico Functional Profiling of Engineered Small Molecules: A Machine Learning Approach Leveraging PubChem Identifiers (CID_SID ML model)](https://arxiv.org/abs/2501.02154)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2501.02154v3 Announce Type: replace 
Abstract: The article introduces a concept for a time- and cost-effective methodological framework leveraging machine learning (ML) models for both early-stage drug development and clinical trial support. The rationale for this approach is the inherent scalability and speed e‚Ä¶

- **[Implicit Generative Modeling by Kernel Similarity Matching](https://arxiv.org/abs/2503.00655)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2503.00655v2 Announce Type: replace 
Abstract: Understanding how the brain encodes stimuli has been a fundamental problem in computational neuroscience. Insights into this problem have led to the design and development of artificial neural networks that learn representations by incorporating brain-like learning‚Ä¶

- **[Fluctuating growth rates link turnover and unevenness in species-rich communities](https://arxiv.org/abs/2505.01376)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2505.01376v2 Announce Type: replace 
Abstract: The maintenance of diversity, the `commonness of rarity', and compositional turnover are ubiquitous features of species-rich communities. Through a minimal model, we consider how these features reflect the interplay between environmental stochasticity, intra- and in‚Ä¶

- **[Look mom, no experimental data! Learning to score protein-ligand interactions from simulations](https://arxiv.org/abs/2506.00593)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2506.00593v3 Announce Type: replace 
Abstract: Despite recent advances in protein-ligand structure prediction, deep learning methods remain limited in their ability to accurately predict binding affinities, particularly for novel protein targets dissimilar from the training set. In contrast, physics-based bindin‚Ä¶

- **[Identifying multi-compartment Hodgkin-Huxley models with high-density extracellular voltage recordings](https://arxiv.org/abs/2506.20233)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2506.20233v2 Announce Type: replace 
Abstract: Multi-compartment Hodgkin-Huxley models are biophysical models of how electrical signals propagate throughout a neuron, and they form the basis of our knowledge of neural computation at the cellular level. However, these models have many free parameters that must be‚Ä¶

- **[The generalized Hierarchical Gaussian Filter](https://arxiv.org/abs/2305.10937)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2305.10937v3 Announce Type: replace-cross 
Abstract: Hierarchical Bayesian models of perception and learning feature prominently in contemporary cognitive neuroscience where, for example, they inform computational concepts of mental disorders. This includes predictive coding and hierarchical Gaussian filtering (‚Ä¶

- **[Asymptotic Analysis of the Total Quasi-Steady State Approximation for the Michaelis--Menten Enzyme Kinetic Reactions](https://arxiv.org/abs/2503.20145)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2503.20145v2 Announce Type: replace-cross 
Abstract: We consider a stochastic model of the Michaelis-Menten (MM) enzyme kinetic reactions in terms of Stochastic Differential Equations (SDEs) driven by Poisson Random Measures (PRMs). It has been argued that among various Quasi-Steady State Approximations (QSSAs)‚Ä¶

- **[ConfRover: Simultaneous Modeling of Protein Conformation and Dynamics via Autoregression](https://arxiv.org/abs/2505.17478)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2505.17478v2 Announce Type: replace-cross 
Abstract: Understanding protein dynamics is critical for elucidating their biological functions. The increasing availability of molecular dynamics (MD) data enables the training of deep generative models to efficiently explore the conformational space of proteins. Howev‚Ä¶

- **[PixCell: A generative foundation model for digital histopathology images](https://arxiv.org/abs/2506.05127)**  
  _Thu, 04 Dec 2025 00:00:00 -0500_  
  arXiv:2506.05127v2 Announce Type: replace-cross 
Abstract: The digitization of histology slides has revolutionized pathology, providing massive datasets for cancer diagnosis and research. Self-supervised and vision-language models have been shown to effectively mine large pathology datasets to learn discriminative rep‚Ä¶
